Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 13/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6838716 | 0.86 | DPP4 (0.53) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6838812 | 0.86 | DPP4 (0.53) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL7010860 | 0.85 | DPP4 (0.46) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL3969586 | 0.85 | DPP4 (0.65) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6843487 | 0.85 | DPP4 (0.54) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6838796 | 0.84 | DPP4 (0.51) | DPP4ALDH1A1TSHRLMNAMAPT | |
| Hydrochloric Acid SCHEMBL3969044 | 0.84 | DPP4 (0.64) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6843776 | 0.83 | DPP4 (0.50) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6843497 | 0.83 | DPP4 (0.45) | DPP4ALDH1A1TSHRLMNAMAPT | |
| SCHEMBL6843652 | 0.83 | DPP4 (0.42) | DPP4ALDH1A1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122228-A1 | New purine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | DPP4 1/4885ALDH1A1 241/4885TSHR 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.